Xi Ming

Xi Ming

Auto-generated profile, based on publicly available information

Xi Ming

Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2026 in Cell Transplantation
Verified
Journal Article
Open access
JWJiaying Wu
Jiaying Wu
RZRubing Zheng
Rubing Zheng
XMXi Ming
Xi Ming
XZXiaojian Zhu
Xiaojian Zhu
MZMi Zhou
Mi Zhou
YXYi Xiao
Yi Xiao
B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T cell therapy has demonstrated promising efficacy in relapsed/refractory multiple myeloma (MM). However, evidence supporting its use in earlier treatment settings remains limited. This study presents a preliminary case series evaluating the feasibility of BCMA CAR-T cell therapy as post-induction consolidation in newly diagnosed multiple myeloma (NDMM) patients who did not proceed to autologous stem cell transplantation (ASCT). Four patients were included in this analysis. After induction therapy, all patients achieved very good partial response or better and did not proceed to ASCT due to ineligibility or personal preference. They subsequently received BCMA CAR-T cell therapy as consolidation treatment. All patients tolerated the BCMA CAR-T cell infusion well. Cytokine release syndrome occurred in all cases, but was limited to grades 1–2, and no immune effector cell–associated neurotoxicity syndrome was observed. Following therapy, patients maintained or further deepened responses and ultimately reached stringent complete response (sCR) and minimal residual disease (MRD) negativity. During a median follow-up period of 17.8 months, all patients remained in sCR status and MRD negativity without the need for additional anti-tumor therapy, and none experienced relapse or disease progression. These preliminary results suggest that BCMA CAR-T cell therapy as post-induction consolidation is feasible and associated with manageable toxicity in NDMM patients not proceeding to ASCT, warranting further evaluation in larger prospective studies.

1 January 2025 in Case Reports in Hematology
Verified
Journal Article
Open access
SYSijia Yan
Sijia Yan
XMXi Ming
Xi Ming
JWJiaying Wu
Jiaying Wu
DPDan Peng
Dan Peng
MZMi Zhou
Mi Zhou
YXYi Xiao
Yi Xiao
Multiple myeloma (MM) is the second most common hematologic malignancy, and patients with relapsed/refractory MM (RRMM) face limited treatment options and a poor prognosis. Recently, CAR‐T cell therapy targeting G‐protein‐coupled receptor, class C group 5 member D (GPRC5D) has shown promising efficacy and safety in preclinical studies, offering new hope for patients with RRMM. We report the successful treatment of a 48‐year‐old female patient with relapsed/refractory nonsecretory MM. The patient had high‐risk factors, including 1q21 amplification and TP53 deletion, and had relapsed after seven lines of therapy, including autologous hematopoietic stem cell transplantation, proteasome inhibitors, immunomodulatory agents, PD‐1 inhibitors, and CD38 monoclonal antibodies. She also developed extramedullary disease. Eventually, she received CAR‐T cell therapy targeting GPRC5D, which led to the complete disappearance of extramedullary lesions and a sustained complete remission lasting up to 17 months. In conclusion, CAR‐T cell therapy targeting GPRC5D is highly effective and well‐tolerated in patients with RRMM, especially those with high‐risk factors. Further studies with larger cohorts and longer follow‐up periods are needed to validate the clinical application of GPRC5D‐targeted CAR‐T cell therapy in RRMM, particularly for patients who have failed BCMA‐targeted therapies.

30 May 2026 in Cell Transplantation
Verified
Journal Article
Open access
XMXi Ming
Xi Ming
XZXiaoying Zhang
Xiaoying Zhang
JWJiaying Wu
Jiaying Wu
WLWanying Liu
Wanying Liu
QZQi Zhang
Qi Zhang
YXYi Xiao
Yi Xiao
This retrospective study evaluated 75 patients with chronic active Epstein–Barr virus infection (CAEBV) to compare the efficacy and survival outcomes of allogeneic hematopoietic stem cell transplantation (HSCT) and programmed death-1 (PD-1) blockade therapy. Patients were classified into HSCT and non-HSCT groups. The primary endpoints were overall response rate (ORR), overall survival (OS), and event-free survival (EFS). HSCT significantly improved ORR, 3-year OS, and 3-year EFS compared to non-HSCT treatment. Subgroup analysis showed that PD-1 blockade achieved outcomes comparable to HSCT in a subset of patients; however, HSCT remained superior, overall, particularly in patients without hemophagocytic lymphohistiocytosis (HLH). The presence of HLH was identified as an independent risk factor for inferior survival. In conclusion, allogeneic HSCT remains the preferred curative strategy for CAEBV, whereas PD-1 blockade represents a promising alternative for carefully selected patients. Early recognition and management of HLH are crucial for improving prognosis.

1 January 2026 in Case Reports in Hematology
Verified
Journal Article
Open access
XZXumeng Zhao
Xumeng Zhao
XMXi Ming
Xi Ming
ZSZhen Shang
Zhen Shang
MZMi Zhou
Mi Zhou
YXYi Xiao
Yi Xiao
Activated phosphoinositide 3‐kinase delta syndrome (APDS) is a rare inborn error of immunity caused by gain‐of‐function variants in PIK3CD and characterized by recurrent infections, lymphoproliferation, and impaired viral control. We report a 17‐year‐old male with a heterozygous PIK3CD c.3061G > A (p.E1021K) variant who presented with progressive edema, extensive hypermetabolic lymphadenopathy, splenomegaly, and Epstein–Barr virus (EBV) DNAemia. A core needle biopsy of the right inguinal lymph node demonstrated an immunodeficiency‐associated EBV‐positive B‐cell lymphoproliferative disorder with extensive monotypic plasmacytoid differentiation. Because the biopsy contained limited mature B‐cell tissue, the pathological findings favored a polymorphic B‐LPD although EBV‐positive diffuse large B‐cell lymphoma with plasmacytic differentiation could not be excluded. The patient received anti‐B‐cell‐directed therapy and supportive treatment. He was subsequently readmitted with septic shock and acute respiratory distress syndrome. Blood metagenomic next‐generation sequencing detected Escherichia coli and Klebsiella pneumoniae , together with antimicrobial‐resistance genes including blaNDM . Despite intensive antimicrobial and organ‐supportive treatment, the patient remained critically ill and was discharged at his family’s request for transfer to a local hospital; his subsequent outcome was unavailable. This case highlights the diagnostic difficulty of classifying EBV‐positive B‐cell proliferations using limited biopsy tissue in APDS and the competing risks of lymphoproliferative disease and severe infection. Adequate tissue sampling and pathological characterization, close microbiological surveillance, and individualized multidisciplinary management are essential in this setting.